Diana Mansour
Research Subjects
Diana Mansour has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Jalal
School of Medicine, Oakland University, Rochester, USA
1 shared publication - Fatimah Jalal1 shared publication
- Mohammad S Aqil1 shared publication
Rami Dali
1 shared publication- Umar Hashim
Endeavor Health Glenview Illinois USA
1 shared publication - Varna Taranikanti
Oakland University William Beaumont School of Medicine
1 shared publication
Latest Publications
- Open Access
- 9 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
From GitHub to Clinic? Small-Scale Validation of Open-Source AI for Diabetic Retinopathy Screening (Preprint)
BACKGROUND Accurate, timely detection of diabetic retinopathy (DR) remains challenging, especially in low‑resource settings with limited ophthalmologic expertise. Open‑source deep learning models offer accessible computer vision tools for DR screening, but their real‑world reliability and clinical readiness are not well established. OBJECTIVE This study evaluates two open‑source models—Proliferative Retinopathy Detection and Bhimrazy Diabetic‑Retinopathy‑Detection—on a publicly available Zenodo fundus image dataset to compare performance characteristics and explore potential clinical roles. METHODS We randomly sampled 100 fundus photographs (50 DR‑positive, 50 DR‑negative) from the Zenodo dataset. Each model generated binary predictions (DR vs. no DR) and confidence scores. Using custom Python scripts, we computed sensitivity, specificity, precision, F1 score, accuracy, and average confidence for correctly identified DR‑positive cases. McNemar's test was used to compare paired classification performance between models. RESULTS The Proliferative model achieved 81% accuracy, with precision of 86% and specificity of 0.88, indicating relatively few false positives and greater reliability for ruling out non‑DR cases. Its F1 score was 0.794, with a mean confidence of 78.2% for correctly identified DR‑positive images. The Bhimrazy model demonstrated higher sensitivity (0.88), detecting more DR‑positive cases, but with lower specificity (0.80) and similar precision (81%), reflecting a modest increase in false positives; its F1 score and accuracy were 0.845 and 0.84, respectively. McNemar's test showed no statistically significant difference in overall classification performance between models (χ² = 0.64, p = 0.42). CONCLUSIONS In this small, single‑dataset evaluation, the Proliferative model showed relatively higher specificity and precision, while the Bhimrazy model demonstrated relatively higher sensitivity, yielding complementary operating characteristics rather than clear superiority of one approach. These findings should be viewed as preliminary and hypothesis‑generating. Larger, multi‑center and prospective validations, including assessment across DR severity thresholds and comparison with ophthalmologist performance, are needed before considering any clinical deployment of these open‑source tools. CLINICALTRIAL N/A
- 9 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessFrom GitHub to Clinic? Small-Scale Validation of Open-Source AI for Diabetic Retinopathy Screening (Preprint)
BACKGROUND Accurate, timely detection of diabetic retinopathy (DR) remains challenging, especially in low‑resource settings with limited ophthalmologic expertise. Open‑source deep learning models offer accessible computer vision tools for DR screening, but their real‑world reliability and clinical readiness are not well established. OBJECTIVE This study evaluates two open‑source models—Proliferative Retinopathy Detection and Bhimrazy Diabetic‑Retinopathy‑Detection—on a publicly available Zenodo fundus image dataset to compare performance characteristics and explore potential clinical roles. METHODS We randomly sampled 100 fundus photographs (50 DR‑positive, 50 DR‑negative) from the Zenodo dataset. Each model generated binary predictions (DR vs. no DR) and confidence scores. Using custom Python scripts, we computed sensitivity, specificity, precision, F1 score, accuracy, and average confidence for correctly identified DR‑positive cases. McNemar's test was used to compare paired classification performance between models. RESULTS The Proliferative model achieved 81% accuracy, with precision of 86% and specificity of 0.88, indicating relatively few false positives and greater reliability for ruling out non‑DR cases. Its F1 score was 0.794, with a mean confidence of 78.2% for correctly identified DR‑positive images. The Bhimrazy model demonstrated higher sensitivity (0.88), detecting more DR‑positive cases, but with lower specificity (0.80) and similar precision (81%), reflecting a modest increase in false positives; its F1 score and accuracy were 0.845 and 0.84, respectively. McNemar's test showed no statistically significant difference in overall classification performance between models (χ² = 0.64, p = 0.42). CONCLUSIONS In this small, single‑dataset evaluation, the Proliferative model showed relatively higher specificity and precision, while the Bhimrazy model demonstrated relatively higher sensitivity, yielding complementary operating characteristics rather than clear superiority of one approach. These findings should be viewed as preliminary and hypothesis‑generating. Larger, multi‑center and prospective validations, including assessment across DR severity thresholds and comparison with ophthalmologist performance, are needed before considering any clinical deployment of these open‑source tools. CLINICALTRIAL N/A